In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.

Ameeta Singh

doi:10.7326/acpj202101190-003

In severe COVID-19, adding lopinavir-ritonavir to usual care did not improve mortality at 28 days.

Ameeta Singh

https://doi.org/10.7326/acpj202101190-003

Copy DOI

Journal: Annals of internal medicine	Publication Date: Jan 1, 2021
Citations: 3

Affiliation: University of Alberta

#Platform Trial #Severe COVID-19 + Show 4 more

Abstract
Full-Text PDF
Similar Papers

Abstract

RECOVERY Collaborative Group. Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2020;396:1345-52. 33031764.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of internal medicine

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.